Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 163

1.

Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline.

Rodvold KA, Pai MP.

Clin Infect Dis. 2019 Aug 1;69(Supplement_1):S16-S22. doi: 10.1093/cid/ciz309.

2.

Omadacycline: a novel aminomethylcycline.

Burgos RM, Rodvold KA.

Infect Drug Resist. 2019 Jul 2;12:1895-1915. doi: 10.2147/IDR.S171352. eCollection 2019. Review.

3.

Safety and Efficacy of Tigecycline to Treat Multidrug-resistant Infections in Pediatrics: An Evidence Synthesis.

Sharland M, Rodvold KA, Tucker HR, Baillon-Plot N, Tawadrous M, Hickman MA, Raber S, Korth-Bradley JM, Díaz-Ponce H, Wible M.

Pediatr Infect Dis J. 2019 Jul;38(7):710-715. doi: 10.1097/INF.0000000000002339.

PMID:
31192975
4.

60 Plus Years Later and We Are Still Trying to Learn How to Dose Vancomycin.

Rodvold KA.

Clin Infect Dis. 2019 Jun 3. pii: ciz467. doi: 10.1093/cid/ciz467. [Epub ahead of print] No abstract available.

PMID:
31157362
5.

Introduction: lefamulin and pharmacokinetic/pharmacodynamic rationale to support the dose selection of lefamulin.

Rodvold KA.

J Antimicrob Chemother. 2019 Apr 1;74(Supplement_3):iii2-iii4. doi: 10.1093/jac/dkz084.

6.

ZTI-01 (fosfomycin for injection) in the treatment of hospitalized patients with complicated urinary tract infections.

Burgos RM, Rodvold KA.

Future Microbiol. 2019 Apr;14:461-475. doi: 10.2217/fmb-2018-0303. Epub 2019 Mar 11. Review.

PMID:
30854892
7.

The Infectious Diseases Society of America's 10 × '20 Initiative (10 New Systemic Antibacterial Agents US Food and Drug Administration Approved by 2020): Is 20 × '20 a Possibility?

Talbot GH, Jezek A, Murray BE, Jones RN, Ebright RH, Nau GJ, Rodvold KA, Newland JG, Boucher HW; Infectious Diseases Society of America.

Clin Infect Dis. 2019 Jun 18;69(1):1-11. doi: 10.1093/cid/ciz089.

PMID:
30715222
8.

Renal Dosing of Antibiotics: Are We Jumping the Gun?

Crass RL, Rodvold KA, Mueller BA, Pai MP.

Clin Infect Dis. 2019 Apr 24;68(9):1596-1602. doi: 10.1093/cid/ciy790.

PMID:
30219824
9.

Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to Healthy Adult Subjects.

Rodvold KA, Gotfried MH, Isaacs RD, O'Donnell JP, Stone E.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01089-18. doi: 10.1128/AAC.01089-18. Print 2018 Nov.

10.

Pharmacokinetic evaluation of meropenem and vaborbactam for the treatment of urinary tract infection.

Burgos RM, Biagi MJ, Rodvold KA, Danziger LH.

Expert Opin Drug Metab Toxicol. 2018 Oct;14(10):1007-1021. doi: 10.1080/17425255.2018.1511702. Epub 2018 Sep 19. Review.

PMID:
30106599
11.

Phase I Study To Evaluate the Pharmacokinetics, Safety, and Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants.

Wenzler E, Bleasdale SC, Sikka M, Bunnell KL, Finnemeyer M, Rosenkranz SL, Danziger LH, Rodvold KA; Antibacterial Resistance Leadership Group.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00464-18. doi: 10.1128/AAC.00464-18. Print 2018 Aug.

12.

Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects.

Rodvold KA, Gotfried MH, Chugh R, Gupta M, Patel A, Chavan R, Yeole R, Friedland HD, Bhatia A.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00682-18. doi: 10.1128/AAC.00682-18. Print 2018 Aug.

13.

Comparison of piperacillin exposure in the lungs of critically ill patients and healthy volunteers.

Felton TW, Ogungbenro K, Boselli E, Hope WW, Rodvold KA.

J Antimicrob Chemother. 2018 May 1;73(5):1340-1347. doi: 10.1093/jac/dkx541.

PMID:
29385448
14.

Pharmacokinetics of Telavancin at Fixed Doses in Normal-Body-Weight and Obese (Classes I, II, and III) Adult Subjects.

Bunnell KL, Pai MP, Sikka M, Bleasdale SC, Wenzler E, Danziger LH, Rodvold KA.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02475-17. doi: 10.1128/AAC.02475-17. Print 2018 Apr.

15.

Intrapulmonary Pharmacokinetics of Levonadifloxacin following Oral Administration of Alalevonadifloxacin to Healthy Adult Subjects.

Rodvold KA, Gotfried MH, Chugh R, Gupta M, Yeole R, Patel A, Bhatia A.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02297-17. doi: 10.1128/AAC.02297-17. Print 2018 Mar.

16.

Considerations for effect site pharmacokinetics to estimate drug exposure: concentrations of antibiotics in the lung.

Rodvold KA, Hope WW, Boyd SE.

Curr Opin Pharmacol. 2017 Oct;36:114-123. doi: 10.1016/j.coph.2017.09.019. Epub 2017 Oct 31. Review.

PMID:
29096171
17.

Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects.

Gotfried MH, Horn K, Garrity-Ryan L, Villano S, Tzanis E, Chitra S, Manley A, Tanaka SK, Rodvold KA.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e01135-17. doi: 10.1128/AAC.01135-17. Print 2017 Sep.

18.

Comparison of Plasma and Intrapulmonary Concentrations of Nafithromycin (WCK 4873) in Healthy Adult Subjects.

Rodvold KA, Gotfried MH, Chugh R, Gupta M, Friedland HD, Bhatia A.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e01096-17. doi: 10.1128/AAC.01096-17. Print 2017 Sep.

19.

Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers.

Wenzler E, Ellis-Grosse EJ, Rodvold KA.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00775-17. doi: 10.1128/AAC.00775-17. Print 2017 Sep.

20.

Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration.

Wenzler E, Bunnell KL, Bleasdale SC, Benken S, Danziger LH, Rodvold KA.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00464-17. doi: 10.1128/AAC.00464-17. Print 2017 Jul.

21.

Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA.

Horn KS, Danziger LH, Rodvold KA, Glowacki RC.

Expert Opin Drug Metab Toxicol. 2017 Apr;13(4):463-472. doi: 10.1080/17425255.2017.1303481. Epub 2017 Mar 17. Review.

PMID:
28264613
22.

Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects.

Wenzler E, Gotfried MH, Loutit JS, Durso S, Griffith DC, Dudley MN, Rodvold KA.

Antimicrob Agents Chemother. 2015 Dec;59(12):7232-9. doi: 10.1128/AAC.01713-15. Epub 2015 Sep 8.

23.

Pharmacokinetics, pharmacodynamics, and safety of USL261, a midazolam formulation optimized for intranasal delivery, in a randomized study with healthy volunteers.

Bancke LL, Dworak HA, Rodvold KA, Halvorsen MB, Gidal BE.

Epilepsia. 2015 Nov;56(11):1723-31. doi: 10.1111/epi.13131. Epub 2015 Sep 2.

24.

Telavancin: the long and winding road from discovery to food and drug administration approvals and future directions.

Wenzler E, Rodvold KA.

Clin Infect Dis. 2015 Sep 15;61 Suppl 2:S38-47. doi: 10.1093/cid/civ522. Review.

PMID:
26316557
25.

Telavancin for the treatment of methicillin-resistant Staphylococcus aureus infections.

Rodvold KA.

Clin Infect Dis. 2015 Sep 15;61 Suppl 2:S35-7. doi: 10.1093/cid/civ524. No abstract available.

PMID:
26316556
26.

Pharmacokinetics of ceftaroline in normal body weight and obese (classes I, II, and III) healthy adult subjects.

Justo JA, Mayer SM, Pai MP, Soriano MM, Danziger LH, Novak RM, Rodvold KA.

Antimicrob Agents Chemother. 2015 Jul;59(7):3956-65. doi: 10.1128/AAC.00498-15. Epub 2015 Apr 20.

27.

Editorial commentary: improving prescribers to advance antimicrobial stewardship.

Wenzler E, Rodvold KA, Danziger LH.

Clin Infect Dis. 2015 Apr 15;60(8):1259-61. doi: 10.1093/cid/civ021. Epub 2015 Jan 16. No abstract available.

PMID:
25595751
28.

Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil.

Merker A, Danziger LH, Rodvold KA, Glowacki RC.

Expert Opin Drug Metab Toxicol. 2014 Dec;10(12):1741-50. doi: 10.1517/17425255.2014.972932. Epub 2014 Oct 27. Review.

PMID:
25347329
29.

Variability in telavancin cross-reactivity among vancomycin immunoassays.

McConeghy KW, Liao S, Clark D, Worboys P, Barriere SL, Rodvold KA.

Antimicrob Agents Chemother. 2014 Dec;58(12):7093-7. doi: 10.1128/AAC.03785-14. Epub 2014 Sep 15.

30.

Innovative approaches to optimizing the delivery of vancomycin in individual patients.

Pai MP, Neely M, Rodvold KA, Lodise TP.

Adv Drug Deliv Rev. 2014 Nov 20;77:50-7. doi: 10.1016/j.addr.2014.05.016. Epub 2014 Jun 5. Review.

31.

Antibacterial resistance leadership group: open for business.

Chambers HF, Bartlett JG, Bonomo RA, Chiou C, Cosgrove SE, Cross HR, Daum RS, Downing M, Evans SR, Knisely J, Kreiswirth BN, Lautenbach E, Mickley BS, Patel R, Pettigrew MM, Rodvold KA, Spellberg B, Fowler VG Jr.

Clin Infect Dis. 2014 Jun;58(11):1571-6. doi: 10.1093/cid/ciu132. Epub 2014 Mar 6. Review.

32.

Methicillin-resistant Staphylococcus aureus therapy: past, present, and future.

Rodvold KA, McConeghy KW.

Clin Infect Dis. 2014 Jan;58 Suppl 1:S20-7. doi: 10.1093/cid/cit614. Review.

PMID:
24343828
33.

Vancomycin: over 50 years later and still a work in progress.

Rybak MJ, Rotschafer JC, Rodvold KA.

Pharmacotherapy. 2013 Dec;33(12):1253-5. doi: 10.1002/phar.1382. No abstract available.

PMID:
24302197
34.

Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy.

Fischer JH, Sarto GE, Hardman J, Endres L, Jenkins TM, Kilpatrick SJ, Jeong H, Geller S, Deyo K, Fischer PA, Rodvold KA.

Clin Pharmacokinet. 2014 Apr;53(4):373-83. doi: 10.1007/s40262-013-0123-0.

35.

Aminoglycoside dosing in patients by kidney function and area under the curve: the Sawchuk-Zaske dosing method revisited in the era of obesity.

Pai MP, Rodvold KA.

Diagn Microbiol Infect Dis. 2014 Feb;78(2):178-87. doi: 10.1016/j.diagmicrobio.2013.10.011. Epub 2013 Oct 22. Review.

PMID:
24268292
36.

Penetration of GSK1322322 into epithelial lining fluid and alveolar macrophages as determined by bronchoalveolar lavage.

Naderer OJ, Rodvold KA, Jones LS, Zhu JZ, Bowen CL, Chen L, Dumont E.

Antimicrob Agents Chemother. 2014;58(1):419-23. doi: 10.1128/AAC.01836-13. Epub 2013 Nov 4.

37.

Are vancomycin trough concentrations adequate for optimal dosing?

Neely MN, Youn G, Jones B, Jelliffe RW, Drusano GL, Rodvold KA, Lodise TP.

Antimicrob Agents Chemother. 2014;58(1):309-16. doi: 10.1128/AAC.01653-13. Epub 2013 Oct 28.

38.

The empirical combination of vancomycin and a β-lactam for Staphylococcal bacteremia.

McConeghy KW, Bleasdale SC, Rodvold KA.

Clin Infect Dis. 2013 Dec;57(12):1760-5. doi: 10.1093/cid/cit560. Epub 2013 Aug 28. Review.

PMID:
23985343
39.

Intrapulmonary pharmacokinetics of GSK2251052 in healthy volunteers.

Tenero D, Bowers G, Rodvold KA, Patel A, Kurtinecz M, Dumont E, Tomayko J, Patel P.

Antimicrob Agents Chemother. 2013 Jul;57(7):3334-9. doi: 10.1128/AAC.02483-12. Epub 2013 May 6.

40.

Prolonged infusions of β-lactam antibiotics: implication for antimicrobial stewardship.

George JM, Towne TG, Rodvold KA.

Pharmacotherapy. 2012 Aug;32(8):707-21. doi: 10.1002/j.1875-9114.2012.01157.x. Review.

PMID:
23307519
41.

National survey on continuous and extended infusions of antibiotics.

George JM, Colton BJ, Rodvold KA.

Am J Health Syst Pharm. 2012 Nov 1;69(21):1895-904. doi: 10.2146/ajhp110562.

PMID:
23111674
42.

Comparison of plasma, epithelial lining fluid, and alveolar macrophage concentrations of solithromycin (CEM-101) in healthy adult subjects.

Rodvold KA, Gotfried MH, Still JG, Clark K, Fernandes P.

Antimicrob Agents Chemother. 2012 Oct;56(10):5076-81. doi: 10.1128/AAC.00766-12. Epub 2012 Jul 16.

43.

Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects.

Chandorkar G, Huntington JA, Gotfried MH, Rodvold KA, Umeh O.

J Antimicrob Chemother. 2012 Oct;67(10):2463-9. doi: 10.1093/jac/dks246. Epub 2012 Jul 6.

PMID:
22773741
44.

Continuation of high-dose vancomycin despite nephrotoxicity.

Teng CB, Rezai K, Itokazu GS, Xamplas RC, Glowacki RC, Rodvold KA, Weinstein RA, Schwartz DN.

Antimicrob Agents Chemother. 2012 Jun;56(6):3470-1; author reply 3472. doi: 10.1128/AAC.00240-12. No abstract available.

45.

Vancomycin for surgical prophylaxis?

Crawford T, Rodvold KA, Solomkin JS.

Clin Infect Dis. 2012 May;54(10):1474-9. doi: 10.1093/cid/cis027. Epub 2012 Feb 10. Review.

PMID:
22328468
46.

Influence of body weight, ethnicity, oral contraceptives, and pregnancy on the pharmacokinetics of azithromycin in women of childbearing age.

Fischer JH, Sarto GE, Habibi M, Kilpatrick SJ, Tuomala RE, Shier JM, Wollett L, Fischer PA, Khorana KS, Rodvold KA.

Antimicrob Agents Chemother. 2012 Feb;56(2):715-24. doi: 10.1128/AAC.00717-11. Epub 2011 Nov 21.

47.

Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents.

Rodvold KA, Yoo L, George JM.

Clin Pharmacokinet. 2011 Nov 1;50(11):689-704. doi: 10.2165/11592900-000000000-00000. Review.

PMID:
21973267
48.

Penetration of vancomycin into epithelial lining fluid in healthy volunteers.

Lodise TP, Drusano GL, Butterfield JM, Scoville J, Gotfried M, Rodvold KA.

Antimicrob Agents Chemother. 2011 Dec;55(12):5507-11. doi: 10.1128/AAC.00712-11. Epub 2011 Sep 12.

49.

Zanamivir pharmacokinetics and pulmonary penetration into epithelial lining fluid following intravenous or oral inhaled administration to healthy adult subjects.

Shelton MJ, Lovern M, Ng-Cashin J, Jones L, Gould E, Gauvin J, Rodvold KA.

Antimicrob Agents Chemother. 2011 Nov;55(11):5178-84. doi: 10.1128/AAC.00703-11. Epub 2011 Sep 6.

50.

Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.

Rodvold KA, George JM, Yoo L.

Clin Pharmacokinet. 2011 Oct;50(10):637-64. doi: 10.2165/11594090-000000000-00000. Review.

PMID:
21895037

Supplemental Content

Loading ...
Support Center